Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: A case report

Journal of Neuro-Oncology

Volumn 107, Issue 3, 2012, Pages 659-663

  Renfrow, Jaclyn J ^a   DeTroye, Alisha ^a   Chan, Michael ^a   Tatter, Stephen ^a   Ellis, Thomas ^a   McMullen, Kevin ^a   Johnson, Annette ^a   Mott, Ryan ^a   Lesser, Glenn J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Bendamustine; Chemotherapy; Recurrent primary CNS lymphoma

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PEMETREXED; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE; ALKYLATING AGENT; CHLORMETHINE DERIVATIVE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; BRAIN RADIATION; CANCER RECURRENCE; CASE REPORT; CHILL; CONFUSION; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HOMONYMOUS HEMIANOPIA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; RADIATION RESPONSE; RECURRENT CANCER; SCOTOMA; SLURRED SPEECH; VISUAL HALLUCINATION; VOMITING; WEAKNESS; CENTRAL NERVOUS SYSTEM TUMOR; MIDDLE AGED; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITROGEN MUSTARD COMPOUNDS;

EID: 84863961203     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0788-x     Document Type: Article

References (24)

1. Kadan-Lottick NS, Skluzacek MC, Gurney JG (2002) Decreasing incidence rates of primary central nervous system lymphoma. Cancer 95(1):193-202
2. Gerstner ER, Carson KA, Grossman SA et al (2008) Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 70(5):401-402
3. Omuro AM, Abrey LE (2006) Chemotherapy for primary central nervous system lymphoma. Neurosurg Focus 21(5):E12
4. Chamberlain MC, Johnston SK (2010) High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol 12(7):736-744
5. Nelson DF, Martz KL, Bonner H et al (1992) Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23(1):9-17
6. DeAngelis LM, Yahalom J, Thaler HT et al (1992) Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10(4):635-643
7. Freilich RJ, Delattre JY, Monjour A et al (1996) Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46:435-439
8. Thiel E, Korfel A, Martus P et al (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11(11):1036-1047
9. Reni M, Ferreri AJ (2001) Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 80(Suppl 2):B113-B117
10. Gerstner ER, Batchelor TT (2010) Primary central nervous system lymphoma. Arch Neurol 67(3):291-297
11. Hottinger AF, DeAngelis LM, Abrey LE (2007) Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69:1178-1182
12. Shah GD, DeAngelis LM (2005) Treatment of primary central nervous system lymphoma. Hematol Oncol Clin North Am 19(4): 611-627
13. Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM et al (2003) Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70:219-224
14. Reni M, Ferreri AJ, Landoni C et al (2000) Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 92:575-576
15. Enting RH, Demopoulos A, DeAngelis LM et al (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63:901-903
16. Fischer L, Thiel E, Klasen HA et al (2004) Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 62(10):1885-1887
17. JK Altman, C Tellez, J Chandler et al. (2008). Phase II trial of recurrent primary CNS lymphoma (PCNSL) treated with pemetrexed. J Clin Oncol 26: May 20 suppl; abstr 2075
18. Cheson B, Wendtner C, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J, Knop S, Montillo M, Rummel M (2010) Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 10(1):21-27
19. Zulkowski K, Kath R et al (2002) Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. J Cancer Res Clin Oncol 128(2):111-113
20. Bendamustine hydrochloride (CEP-18083) (INVESTIGATOR'S BROCHURE), Cephalon Edition 2, Release on: 4 Mar 2010
21. Leoni LM, Bailey B et al (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14(1):309-317
22. Roué G, López-Guerra M, Milpied P et al (2008) Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 14(21):6907-6915
23. Chamberlain MC, Johnston SK (2011) Salvage therapy with single agent bendamustine for recurrent glioblastoma. J Neurooncol 105:523-530
24. Hodson DJ, Bowles KM, Cooke LJ et al (2005) Primary central nervous system lymphoma: a single-centre experience of 55 unselected cases. Clin Oncol (R Coll Radiol) 17(3):185-191